Technology-Ready Processes for Gene Therapy Manufacturing 2.0

Technology-Ready Processes for
Gene Therapy Manufacturing 2.0

Please join us for this free, live Ask the Expert webcast.

Just fill out the form below to register.

Presenter:

René Gantier, PhD

Director of Technology, Gene Therapy

Repligen

René Gantier is currently the Director of Technology for Gene Therapy at Repligen. He brings nearly 20 years’ experience in developing production and purification processes for biotherapies. He started his career in the biotechnology industry as a scientist, developing long-lasting therapeutic cytokines at Nautilus Biotech in France before joining Pall Life Sciences as a downstream processing field application specialist. He expanded his role to lead the Biotech Process R&D team, developing end-to-end upstream–downstream continuous bioprocessing solutions for monoclonal antibodies and cell/gene therapies. His primary role at Repligen is to provide technology guidance in the development of high-productivity, next-generation gene-therapy manufacturing processes. René holds a MSc in cell biology from the University of Nantes, France, and a PhD in biochemistry from the University of Rouen, France.

About this event:

Date: May 21, 2020

Time: 11 am EDT | 8 am PDT |
5 pm CEST

Duration: 15 minutes

The current manufacturing processes for viral vectors for gene therapy, which we can define as Gene Therapy Manufacturing 1.0 (e.g., adherent cell culture and transient expression from plasmid transfection), are not productive enough to meet the future demand considering the quickly increasing number of approved gene therapies and clinical trials. A transition is therefore ongoing to implement more productive and scalable processes, leading to Gene Therapy Manufacturing 2.0 using suspension cell culture and developing producer cell lines. Adopting the right technology solutions on this journey is essential.

In this talk we will

Evaluate the near-future needs for gene therapy manufacturing
Discuss the major technology challenges posed to quickly develop high-productivity, -safety, and -quality manufacturing processes for viral vectors
Propose technology solutions for upstream (perfusion cell culture) and downstream (tangential-flow filtration and chromatography) processing to overcome these challenges.